Rapport Therapeutics issues $172.5 million in 2.25% convertible senior notes due 2032

Bitget2026/10/30 21:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rapport Therapeutics issued $172.5 million of convertible senior notes on October 30, 2026, raising approximately $166.8 million net.
Morgan Stanley, Leerink Partners and Evercore represented the underwriters under an agreement signed October 28, 2026.
The general unsecured notes carry a 2.25% annual interest rate and mature December 1, 2032.
Conversions will settle in common stock at an initial conversion price of approximately $26.775 per share, subject to adjustments.
Offering proceeds will primarily fund RAP-219 clinical trials, other research and development, and working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-441851), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rapport Therapeutics issues $172.5 million in 2.25% convertible senior notes due 2032

You may also like

Crypto prices